期刊文献+

麻黄非生物碱类成份对高脂血症模型小鼠脂质代谢的影响 被引量:9

下载PDF
导出
摘要 目的观察麻黄非生物碱类成分对实验性高脂血症小鼠脂质代谢的影响。方法喂饲法建立高脂血症小鼠模型,实验设空白组、模型组、阳性组、麻黄生物碱组和麻黄非生物碱组共5组,灌胃给药4周,每周称重1次。4周后,分别测定血清中TC、TG、HDL-C、MDA含量和ALT、AST、SOD的活性。结果灌胃给药4周后,与模型组比较,阳性组、麻黄生物碱组和麻黄非生物碱组均显著降低小鼠TC水平,升高HDL-C水平;麻黄生物碱组和麻黄非生物碱组显著降低TG水平;麻黄非生物碱组显著升高血清中SOD活性和显著显著降低MDA含量,麻黄生物碱组显著降低SOD活性;麻黄非生物碱组中ALT、AST活性均显著降低,而阳性组和麻黄生物碱组升高其活性。结论中药麻黄非生物碱类成分有拮抗高脂血症的功效。
出处 《湖北中医杂志》 2011年第6期3-5,共3页 Hubei Journal of Traditional Chinese Medicine
  • 相关文献

参考文献11

  • 1Shekelle PG.Efficacy and safety of ephedra and ephedrinefor weight loss and athletic performance[J].A meta-analysis.JAMA,2003,26(289):1537-45.
  • 2Kalman D,Incledon T,Gaunaurd I,et al.An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra-caffeine weight loss product in healthy overweight adults[J].Int J Obes Relat Metab Disord,2002,(26):1363 6.
  • 3Haller CA,Benowitz NL.Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids[J].N Engl J Med,2000(343):1833.
  • 4ChumbalovTK,ChekmenevaLN,PolyakovVV.Phenolic acids ofEphedra equisetin[J].Khim Prir Soedin,1977,(2):278.
  • 5Xiu L M,Mira A B,Yamamoto K,et al.Pancreatic regeneration by ephedrine in mice with streptozotocin induced diabetes[J].American Journal of Chinese Medicine,2001,29 (3-4):493.
  • 6张连茹,邹国林,杨天鸣.麻黄水溶性多糖的提取及其清除氧自由基作用的研究[J].氨基酸和生物资源,2000,22(3):24-26. 被引量:40
  • 7文镜,张静,桑婷婷,王燕伟,蒋艾.用高血脂小鼠模型评价降血脂保健食品可行性的探讨[J].食品科学,2006,27(11):479-482. 被引量:27
  • 8Chin J H,Abdelhadi RH,Chung MK,et al.Effect of statin therapy on risk of ventricular arrhythm in among patients with coronary artery disease and an inplantable cardioverter-defibrillator[J].Am J Cardiol,2005,95 (4):490-491.
  • 9Conforti A,Magro L,Moretti U,et al.Fluvastatin and hepatic reactions:a signal from spontaneous reporting in Italy[J].Drug Saf,2006,29 (12):1163-1172.
  • 10王广华 ,邢象斌 .非酒精性脂肪肝的发病机制研究进展[J].黑龙江医学,2004,28(4):273-274. 被引量:5

二级参考文献21

  • 1闫志芳,王永辉,刘季英,张荣.建立高血脂症动物模型的实验研究[J].山西中医学院学报,2004,5(4):15-16. 被引量:15
  • 2邹国林.对SOD研究中若干问题的看法[J].中国生化药物杂志,1995,16(4):186-189. 被引量:30
  • 3[1]Alter M J,ruszzon D,Nainan D V,et al.Te prevalence of epatitis C virus infection in te united states,1988 troug 1994[J].N Engl J Med,1999,341(8):556~562.
  • 4[2]Marcesini G,Brizi M,Bianci G,et al.Nonalcoolic fatter liver disease:a feature of te metabolic syndrome[J].Dia betes,2001,50(8):1 844~1 850.
  • 5[3]Paradis V,Perlemuter G,Bonvoust F,et al.ig glucose and yperinsulinemia stimulate connective tissue growt factor expression:a potential mecanism involved in progression to fibrosis in nonalcoolic steatoepatitis[J].epatology,2001,34(1):738~744.
  • 6[4]Rasid I,Roberts E A.Nonalcoolic steatoepatitis in cildren[J].J Pediatr Gastroenterol Nutr,2002,30(6):48~53.
  • 7[5]im J ,im Y T,Fillmore J J,et al.Prevetion of fat-induced insulin resistance by salicylate[J].J Clin Invest,2001,108(3):437~446.
  • 8[6]Sanyal A J,Campbell-sargent C,Mirsai F,et al.Nonalcoolic steatoepatitis:association of insulin resistance and mitocondrial abnormalities[J].Gasteroenterology,2001,120(5):1 183~1 192.
  • 9[7]Leclereq Z A,Farrel G C,Field J,et al.CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nnalcoolic steatoepatitis[J].J Clin Invest,2000,105(8):1 067~1 075.
  • 10[8]Angulo P.Nonalcoolic fatter liver disease[J].N Engl J Med,2002,346(16):1 221~1 231.

共引文献212

同被引文献182

引证文献9

二级引证文献352

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部